NEW YORK, Oct. 10 - GlaxoSmithKline and First Genetic Trust have entered into a broad SNP-related research collaboration to define why some individuals are susceptible to certain serious adverse events, the companies said on Wednesday.

GlaxoSmithKline will sponsor the study and conduct all analyses, while First Genetic Trust will provide its independent secure genetic banking services to store biological samples and medical data.

First Genetic Trust will also ensure that participating patients’ privacy is protected.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.